The First Appellate Authority in Ahmedabad has set aside a penalty of INR 3,59,10,000 imposed on Maxcure Nutravedics Limited, a wholly-owned subsidiary of Akums Drugs & Pharmaceuticals . The order, dated July 03, 2026, reverses the earlier decision by the Deputy Commissioner of State Tax, Gujarat, providing relief to the subsidiary regarding a tax dispute arising from invoicing errors in October 2025.

The penalty was initially levied because the shipping address was mistakenly entered incorrectly in the invoice and e-way bill for October 2025. Following an appeal, the First Appellate Authority reviewed the case and vacated the penalty, effectively removing the financial liability that had been proposed against the subsidiary.

Akums Drugs and Pharmaceuticals Limited stated that there will be no financial impact on the company as a result of this order. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Details of the Order

Akums Drugs and Pharmaceuticals Ltd has reported a 5.9% rise in consolidated revenue to ₹43,590.17 Million for the financial year 2025-26 (FY26). The company’s EBITDA improved 13.3% to ₹5,220.30 Million, while Adjusted Profit After Tax rose 27.3% to ₹2,760 Million. The Integrated Annual Report for FY26 was released on June 18, 2026, detailing the financial performance and operational expansion.

Financial Performance

Consolidated revenue from operations increased to ₹43,590.17 Million in FY26 from ₹41,181.58 Million in FY25, while total income grew 7.6% to ₹44,877.42 Million. EBITDA margins expanded to 12.0% from 11.2%. The company reported a net cash position of ₹16,087 Million as of March 31, 2026.

Segment-Wise Performance

The Contract Development and Manufacturing Organisation (CDMO) segment drove growth, contributing approximately 80% of consolidated revenue with an 8.6% year-on-year increase. Domestic Branded Formulations EBITDA grew 17%, while International Branded Formulations EBITDA surged 32.3%.

Global Expansion and AGM Details

Akums Healthcare (Zambia) Private Limited was incorporated on October 13, 2025, as a 51:49 joint venture with the Zambian government. The $45 Million facility in Lusaka is slated to begin operations in CY 2028, with the government committing to procure USD 25 Million annually for FY27 and FY28. In Europe, the company initiated commercial dispatches to Switzerland and incorporated subsidiaries in the UK and Malta.

The 22nd AGM is scheduled for Friday, July 10, 2026, at 11:00 A.M. (IST) through Video Conferencing (VC) and Other Audio-Visual Means (OAVM). Remote e-voting will be available from Monday, July 6, 2026, at 9:00 A.M. (IST) to Thursday, July 9, 2026, at 5:00 P.M. (IST). Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners as on the cut-off date of July 3, 2026, are entitled to vote.